Volrustomig

Phase 3Small molecule

Volrustomig is one of 271 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

270

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Pleural MesotheliomaActive, not recruiting

Cervical CarcinomaRecruiting

Metastatic Colorectal CancerRecruiting

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Cervical CancerActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Pleural MesotheliomaPhase 3

Active, not recruiting

Cervical CarcinomaPhase 2

Recruiting

Metastatic Colorectal CancerPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Volrustomig

AstraZeneca

Phase 3

3 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

REGN2810

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Gastric Cancer

NCT04379596

Phase 1Recruiting

Non-Squamous NSCLC

NCT04686305

Q3 2027

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT06448754

Q4 2027

Phase 2Recruiting

Advanced Solid Tumours

NCT05489211

Phase 2Active, not recruiting

Hepatocellular Carcinoma

NCT05775159

Q3 2028

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT06792695

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05984277·1,200 enrolled

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06448754·180 enrolled

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05061550·630 enrolled

Non-squamous NSCLC1 trial

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04686305·244 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05702229·163 enrolled

Head and Neck Cancer1 trial

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

Recruiting·UUniversity of Chicago·Phase 2·NCT07065630·38 enrolled

Efficacy and Safety1 trial

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07000149·1,116 enrolled

11 more indications

Pleural Mesothelioma1 trial

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06097728·825 enrolled

Advanced Solid Tumours1 trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05489211·454 enrolled

Cancer1 trial

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting·PPresage Biosciences·Phase 1·NCT04541108·15 enrolled

Cervical Cancer1 trial

A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06943833·30 enrolled

Metastatic Colorectal Cancer1 trial

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06792695·80 enrolled

Gastric Cancer1 trial

A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT04379596·450 enrolled

Cervical Carcinoma1 trial

A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06535607·257 enrolled

Hepatocellular Carcinoma1 trial

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05775159·294 enrolled

Locally Advanced Cervical Cancer1 trial

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06079671·800 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592

Completed·PPresage Biosciences·Phase 1·NCT06366451·17 enrolled

Locally Advanced Head and Neck Squamous Cell Carcinoma1 trial

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06129864·1,145 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Volrustomig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Volrustomig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Volrustomig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Volrustomig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q3 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Non-squamous NSCLC1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Head and Neck Cancer1 trial

Efficacy and Safety1 trial

Pleural Mesothelioma1 trial

Advanced Solid Tumours1 trial

Cancer1 trial

Cervical Cancer1 trial

Metastatic Colorectal Cancer1 trial

Gastric Cancer1 trial

Cervical Carcinoma1 trial

Hepatocellular Carcinoma1 trial

Locally Advanced Cervical Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Locally Advanced Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News